Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
September 22 2017 - 7:00AM
Business Wire
Late-breaking oral presentation to focus on
Optune five-year survival and health-related quality of life
data
Novocure (NASDAQ:NVCR) announced today four presentations on
Tumor Treating Fields (TTFields) at the American Society for
Radiation Oncology’s (ASTRO) 2017 Annual Meeting, September 24
through September 27 in San Diego. A late-breaking oral
presentation will focus on Novocure’s EF-14 phase 3 pivotal trial.
This marks the first presentation of EF-14 five-year survival and
quality of life data at a radiation oncology conference. A second
oral presentation will highlight new preclinical data on the
effects of TTFields in delaying DNA damage repair following
radiation treatment of glioma cells.
“We are excited to have a variety of research on TTFields
presented at ASTRO’s 2017 Annual Meeting,” said Dr. Eilon Kirson,
Novocure’s Chief Science Officer and Head of Research and
Development. “Radiation oncologists are our second largest
community of treating physicians for Optune. We appreciate the
opportunity to continue our dialogue through the exchange of
scientific information at the premier meeting for radiation
oncologists.”
The following will be presented at the ASTRO 2017 Annual
Meeting:
Late-breaking oral presentation(LBA-6) Tumor Treating
Fields (TTFields) – A novel cancer treatment modality: Translating
preclinical evidence and engineering into a survival benefit with
delayed decline in quality of life. R. Stupp. 3:15 – 4:15 p.m. PST
on Sunday, September 24. (Location: Ballroom 20)
Oral presentation(68) Tumor Treating Fields (TTFields)
Delay DNA Damage Repair Following Radiation Treatment of Glioma
Cells: Implications for Irradiation through TTFields Transducer
Arrays. M. Story. 7:45 to 9 a.m. PST on Monday, September 25.
(Location: Room 4)
Poster presentation(3530) Creating patient-specific
computational head models for the study of tissue-electric field
interactions using deformable templates. N. Urman. 4:15 to 5:45
p.m. PST on Monday, September 25. (Location: Poster Hall)
(3529) Measuring the electric properties of human skin in order
to understand how Tumor Treating Fields distribute within the body.
H. Hershkovich. 4:15 to 5:45 p.m. PST on Monday, September 25.
(Location: Poster Hall)
About Novocure
Novocure is an oncology company developing a profoundly
different cancer treatment utilizing a proprietary therapy called
TTFields, the use of electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s
commercialized product, Optune, is approved for the treatment of
adult patients with glioblastoma. Novocure has ongoing or completed
clinical trials investigating TTFields in brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and
mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.
Additionally, the company has offices in Germany, Switzerland,
Japan and Israel. For additional information about the company,
please visit www.novocure.com or follow us at
www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2017, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170922005283/en/
Media and Investors:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024